Montelukast improves symptoms of seasonal allergic rhinitis over a 4‐week treatment period
Authors:
- G. PhilipGPG. Philip
- A. J. PedinoffAPA. J. Pedinoff
- E. O. MeltzerEME. O. Meltzer
- P. H. RatnerPRP. H. Ratner
- J. MentenJMJ. Menten
- T. F. ReissTRT. F. Reiss
- for the Montelukast Fall Rhinitis Study GroupFGfor the Montelukast Fall Rhinitis Study Group
Abstract
Background: Proinflammatory mediators such as the cysteinyl leukotrienes are important in the pathophysiology of allergic rhinitis. This study evaluated the efficacy and tolerability of montelukast, a cysteinyl leukotriene receptor antagonist, given once daily in the morning for treatment of seasonal (fall) allergic rhinitis for 4 weeks.Methods: This was a randomized, double‐blind trial with a placebo run‐in and a 4‐week treatment period. Patients (n = 1079) with a history of allergic rhinitis and a positive skin test to seasonal pollen allergens were assigned to placebo, montelukast 10 mg, or loratadine 10 mg. Symptoms were assessed with a daily diary.Results: Montelukast was more effective than placebo in improving scores for the primary endpoint of daytime nasal symptoms (P = 0.003) and the secondary endpoints of night‐time, composite, and daytime eye symptoms, patient's and physician's global evaluations of allergic rhinitis, and rhinoconjunctivitis quality‐of‐life (P ≤ 0.006). The positive control loratadine also improved scores for the primary endpoint (P ≤ 0.001) and the majority of the secondary endpoints (P < 0.03). When analyzed by week, the treatment effect of montelukast was more persistent than loratadine over all 4 weeks of treatment.Conclusion: Montelukast provided effective relief of seasonal allergic rhinitis symptoms when given once daily in the morning, showed significant and sustained improvement in symptoms of allergic rhinitis over 4 weeks of treatment, and was well‐tolerated.Keywords
This publication has 19 references indexed in Scilit:
- Montelukast for treating seasonal allergic rhinitis: a randomized, double‐blind, placebo‐controlled trial performed in the springClinical & Experimental Allergy, 2002
- Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fallAnnals of Allergy, Asthma & Immunology, 2002
- Allergic Rhinitis and Its Impact on AsthmaJournal of Allergy and Clinical Immunology, 2001
- Antiallergic effects of H1‐receptor antagonistsAllergy, 2000
- Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 2000
- Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trialJournal of Allergy and Clinical Immunology, 2000
- Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of “one linked airway disease”Annals of Allergy, Asthma & Immunology, 2000
- Immunobiology of Asthma and Rhinitis: Pathogenic Factors and Therapeutic OptionsAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Montelukast Dose Selection in 6‐ to 14‐Year‐Olds: Comparison of Single‐Dose Pharmacokinetics in Children and AdultsThe Journal of Clinical Pharmacology, 1999
- Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitisClinical & Experimental Allergy, 1991